Publikationen (22) Publikationen von María Abáigar Alvarado

2021

  1. Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients

    Annals of Hematology, Vol. 100, Núm. 8, pp. 1995-2004

  2. Co-occurrence of cohesin complex and Ras signaling mutations during progression from myelodysplastic syndromes to secondary acute myeloid leukemia

    Haematologica, Vol. 106, Núm. 8, pp. 2215-2223

  3. Multicenter Next-Generation Sequencing Studies between Theory and Practice: Harmonization of Data Analysis Using Real-World Myelodysplastic Syndrome Data

    The Journal of molecular diagnostics : JMD, Vol. 23, Núm. 3, pp. 347-357

  4. NEMHESYS - European Perspective on the Implementation of Next-generation Sequencing Into Clinical Diagnostics

    HemaSphere, Vol. 5, Núm. 3, pp. E541

2020

  1. Genome-wide transcriptomics leads to the identification of deregulated genes after deferasirox therapy in low-risk MDS patients

    Pharmacogenomics Journal, Vol. 20, Núm. 5, pp. 664-671

  2. Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia

    British Journal of Haematology

2019

  1. CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase

    Leukemia, Vol. 33, Núm. 2, pp. 518-558

  2. Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation

    Annals of Hematology, Vol. 98, Núm. 9, pp. 2151-2162

2017

  1. A two-step approach for sequencing spliceosome-related genes as a complementary diagnostic assay in MDS patients with ringed sideroblasts

    Leukemia Research, Vol. 56, pp. 82-87

  2. Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia

    British Journal of Cancer, Vol. 117, Núm. 2, pp. 256-265

  3. Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes

    Oncotarget, Vol. 8, Núm. 63, pp. 106948-106961

2016

  1. Chromothripsis is a recurrent genomic abnormality in high-risk myelodysplastic syndromes

    PLoS ONE, Vol. 11, Núm. 10

  2. Genome-Wide DNA Copy Number Analysis of Acute Lymphoblastic Leukemia Identifies New Genetic Markers Associated with Clinical Outcome

    PloS one, Vol. 11, Núm. 2, pp. e0148972

  3. Identification of expression patterns in the progression of disease stages by integration of transcriptomic data

    BMC Bioinformatics, Vol. 17

2015

  1. ACGH-MAS: Analysis of aCGH by means of multiagent system

    BioMed Research International, Vol. 2015

  2. Deregulation of genes related to iron and mitochondrial metabolism in refractory anemia with ring sideroblasts

    PLoS ONE, Vol. 10, Núm. 5

  3. Fluorescence in situ hybridization analysis does not increase detection rate for trisomy 8 in chronic myelomonocytic leukemia

    Leukemia and Lymphoma

2013

  1. Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): A study on 852 patients

    Leukemia

  2. Prognostic impact of the number of methylated genes in myelodysplastic syndromes and acute myeloid leukemias treated with azacytidine

    Annals of Hematology, Vol. 92, Núm. 11, pp. 1543-1552

  3. Single nucleotide polymorphism array karyotyping: A diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing

    Genes Chromosomes and Cancer, Vol. 52, Núm. 12, pp. 1167-1177